Smoking Cessation: World Markets

Smoking Cessation: World Markets

Smoking cessation is among the most dynamic pharmaceutical markets, and one that is expected to grow despite economic conditions. More than 5 million deaths are attributed to nicotine each year. This has encouraged public health entities to pursue smoking cessation, and has driven development of smoking cessation products, both prescription and over the counter. The arrival of Chantix/Champix and its unique marketing strategy and a robust pipeline bodes well for growth in this pharmaceutical segment.

This report, Smoking Cessation: World Markets takes a thorough look at the products, key players, and important trends in smoking cessation.

The specific segments outlined in the worldwide smoking cessation market include Prescription Drugs as well as OTC. As part of its coverage of the current market for smoking cessation, this report includes:

• Reviews of Products in the Marketplace
  
  
• Market Estimates and Projections
  
  
• World Population and Smoker Population
  
  
• Health Statistics Related to Smoking
  
  
• Issues and Trends

A truly global report, each market chapter provides an overview of products in the segment, market estimates and forecasts, and competitor analysis for US, Europe and the Rest of World.

Issues and trends explored in this study include:

• Tobacco Use
  
  
• Cigar Smoking
  
  
• Life Expectancy
  
  
• Demographics
  
  
• Cancer Statistics
  
  
• Economic Trends
  
  
• Smoking Bans

Leading Competitors Only a handful of companies are involved in the worldwide smoking cessation market. Even fewer hold significant market positions. The top competitors identified and discussed in the smoking cessation market include:

• GlaxoSmithKline
  
  
• McNeil Consumer
  
  
• Novartis
  
  
• Perrigo Company
  
  
• Pfizer

The information for this report was gathered using both primary and secondary research including comprehensive research of secondary sources such as company literature, databases, investment reports, and medical and business journals. Telephone interviews and email correspondence were the primary method of gathering information. For the purpose of this study, Kalorama Information conducted interviews with more than 20 key industry officials, consultants, health care providers, and government personnel. These sources were the primary basis in gathering information specifically relating to revenue and market share data presented in this report. Additional interviews were completed with relevant company representatives including marketing directors, division managers, and product representatives.

All market data pertains to the world market at the manufacturers’ level. The base year for data was 2007. Historical data was provided for the years 2005 and 2006, with forecast data provided for 2008 through 2012. Compound annual growth rates (CAGRs) are provided for the 2005-2007 and 2008-2012 periods for each region and/or segment covered. The forecasted market analysis for 2008-2012 was largely based on demographic trends, new developments, and global expansion.

 
 

TABLE OF CONTENTSCHAPTER ONE: EXECUTIVE SUMMARY

• Overview
  
  
• Scope and Methodology
  
  
• Size and Growth of the Market
  
  
• Key Issues and Trends Affecting the Market
  
  
• Leading Competitors

CHAPTER TWO: INTRODUCTION

• Overview
  
  
• Structure and Function of the Respiratory System
  
  
• Mechanics of Breathing
  
  
• World Tobacco Use
  
  
• Economic Impact
  
  
• Reduced Life Expectancy
  
  
• Tobacco Addiction Compared to Other Addictions
  
  
• Trends in Cigar Smoking
  
  
• Chronic Bronchitis
  
  
• Emphysema
  
  
• Lung Cancer
  
  
• World Cancer Statistics and Tobacco Use
  
  
• Lung Cancer Statistics
  
  
• World Demographics
  
  
• Impact of Smoking Bans

CHAPTER THREE: PRESCRIPTION SMOKING CESSATION MARKETS

• Overview and Summary
  
  
• Chantix/Champix
  
  
• Nicotrol
  
  
• Zyban
  
  
• Market Overview
  
  
  
  
  
  • Market Analysis by Country (US, Europe, Rest of World)
    
    
  • Competitive Analysis

CHAPTER FOUR: OVER-THE-COUNTER SMOKING CESSATION MARKETS

• Overview and Summary
  
  
• Nicorette
  
  
• Nicoderm CQ
  
  
• Nicotrol
  
  
• Habitrol
  
  
• Commit
  
  
• Market Overview
  
  
  
  
  
  • Market Analysis by Country
    
    
  • Competitive Analysis

CHAPTER FIVE: NEW DEVELOPMENT

• Phase II
  
  
• NIC 002 (previously called Cyt002-NicQb)
  
  
• NicVAX
  
  
• Phase I
  
  
• ARD 1600
  
  
• Late Stage Lung Cancer Vaccine Development
  
  
• Lucanix
  
  
• MAGE-A3 Peptide
  
  
• Stimuvax
  
  
• EGF Cancer Vaccine

CHAPTER SIX: MARKET AND COMPETITOR ANALYSIS

• Overview and Summary
  
  
• Market Analysis by Product Type
  
  
• Market Analysis by Country
  
  
• Competitive Analysis

CHAPTER SEVEN: LEADING MANUFACTURERS

• Overview
  
  
• Glaxo Smith Kline
  
  
• McNeil Consumer
  
  
• Novartis Consumer
  
  
• Perrigo Company
  
  
• Pfizer

APPENDIX: LIST OF COMPANIES

TABLE OF EXHIBITS

CHAPTER ONE: EXECUTIVE SUMMARY

• Table 1-1: Total Worldwide Smoking Cessation Market Analysis, 2005-2007
  
  
• Table 1-2: Total Worldwide Smoking Cessation Market Analysis: 2008-2012
  
  
• Figure 1-1: Total Worldwide Smoking Cessation Market Analysis: 2005-2012

CHAPTER TWO: INTRODUCTION

• Table 2-1: Percent of Smokers by Country (United States, Denmark, Finland, France, Iceland, Italy, Japan, Netherlands, New Zealand, Norway, Sweden, UK)
  
  
• Figure 2-1: Average Percent of Smokers Worldwide in Developed Regions
  
  
• Table 2-2: Average Life Expectancy in Years by Country 1980 and 2006
  
  
• Figure 2-2: Average Life Expectancy in Years by Country 1980 and 2006
  
  
• Figure 2-3: United States Estimated Person-Years of Life Lost Due to Cancer, All Races, Both Sexes, 2004
  
  
• Table 2-3: Estimated World Prevalence of Addictions
  
  
• Figure 2-4: Estimated World Prevalence of Addictions
  
  
• Table 2-4: Cigar use in the U.S. by Race, 2005
  
  
• Figure 2-5: Cigar use in the U.S. by Race, 2005
  
  
• Table 2-5: Types of Primary Lung Cancer
  
  
• Table 2-6: Estimated World Incidence of Lung Cancer by Country, 2007 (United States, Germany, France, United Kingdom, Canada, Japan, China, Brazil, Australia, India, Russia, World)
  
  
• Figure 2-6: Estimated World Incidence of Lung Cancer by Country, 2007 (United States, Germany, France, United Kingdom, Canada, Japan, China, Brazil, Australia, India, Russia, World)
  
  
• Figure 2-7: New Lung Cancer Cases and Deaths for 2008 by Gender, United States
  
  
• Table 2-7: New Cases of Lung and Bronchus Cancer by State; Deaths from Lung and Bronchus Cancer by State, 2008 Estimates
  
  
• Table 2-8: World Population by Selected Geographical Region, 2007 - 2050
  
  
• Figure 2-8: World Population by Selected Geographical Region, 2007-2050
  
  
• Table 2-9: Estimated World Population by Age and Geographical Region, 2007
  
  
• Figure 2-9: Estimated World Population by Age and Geographical Region, 2007
  
  
• Table 2-10: Percent Population Over 65 by Year and Region
  
  
• Figure 2-10: Estimated World Population by Age, 2007 and 2050
  
  
• Table 2-11: List of Select Countries with Smoking Bans

CHAPTER THREE: PRESCRIPTION SMOKING CESSATION MARKETS

• Table 3-1: Comparison of Prescription Smoking Cessation Treatments
  
  
• Figure 3-1: Chantix/Champix Sales Analysis, 2006-2007
  
  
• Table 3-2: Prescription Smoking Cessation Market Analysis, 2005-2007
  
  
• Table 3-3: Prescription Smoking Cessation Market Analysis: 2008-2012
  
  
• Figure 3-2: Prescription Smoking Cessation Market Analysis: 2005-2012
  
  
• Table 3-4: Prescription Smoking Cessation Market Analysis by Region/Country, 2007
  
  
• Figure 3-3: Prescription Smoking Cessation Market Analysis by Region/Country, 2007
  
  
• Table 3-5: Prescription Smoking Cessation Market Estimated Revenues and Market Share of Leading Suppliers 2007
  
  
• Figure 3-4: Prescription Smoking Cessation Market Estimated Market Share by Leading Suppliers 2007

CHAPTER FOUR: OVER-THE-COUNTER SMOKING CESSATION MARKETS

• Table 4-1: OTC Nicotine Replacement Therapies by Marketer and OTC Approval Date (FDA)
  
  
• Table 4-2: Over-the-Counter Smoking Cessation Market Analysis, 2005-2007
  
  
• Table 4-3: Over-the-Counter Smoking Cessation Market Analysis: 2008-2012
  
  
• Figure 4-1: Over-the-Counter Smoking Cessation Market Analysis: 2005-2012
  
  
• Table 4-4: Over-the-Counter Smoking Cessation Market Analysis by Region/Country, 2007 (US, Europe, Rest of World)
  
  
• Figure 4-2: Over-the-Counter Smoking Cessation Market Analysis by Region/Country, 2007 (US, Europe, Rest of World)
  
  
• Table 4-5: Over-the-Counter Smoking Cessation Market Estimated Revenues and Market Share of Leading Suppliers 2007
  
  
• Figure 4-3: Over-the-Counter Smoking Cessation Market Estimated Market Share by Leading Suppliers 2007

CHAPTER FIVE: NEW DEVELOPMENT

• Figure 5-1: Smoking Cessation Treatments in Development 2006 and 2008
  
  
• Table 5-1: Smoking Cessation Treatments in Development

CHAPTER SIX: MARKET AND COMPETITOR ANALYSIS

• Table 6-1: Total Worldwide Smoking Cessation Market Analysis, 2005-2007
  
  
• Table 6-2: Total Worldwide Smoking Cessation Market Analysis: 2008-2012
  
  
• Figure 6-1: Total Worldwide Smoking Cessation Market Analysis: 2005-2012
  
  
• Table 6-3: Smoking Cessation Market Analysis by Type, 2005-2007
  
  
• Figure 6-2: Smoking Cessation Market Analysis by Drug Type, 2005-2007 (Prescription, OTC)
  
  
• Figure 6-3: Smoking Cessation Market Share by Drug Type, 2005 (Prescription, OTC)
  
  
• Figure 6-4: Smoking Cessation Market Share by Drug Type, 2007 (Prescription, OTC)
  
  
• Table 6-4: Smoking Cessation Market Analysis by Region/Country, 2007 (US, Europe)
  
  
• Figure 6-5: Smoking Cessation Market Analysis by Region/Country, 2007
  
  
• Table 6-5:Smoking Cessation Market Estimated Revenues and Market Share of Leading Suppliers 2007
  
  
• Figure 6-6: Smoking Cessation Market Estimated Market Share by Leading Suppliers 2007